MCD
MCID: MLT113
MIFTS: 46

Multicentric Castleman Disease (MCD) malady

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Multicentric Castleman Disease

Aliases & Descriptions for Multicentric Castleman Disease:

Name: Multicentric Castleman Disease 50
Multicentric Plasma Cell Variant of Castleman's Disease 50
Plasmablastic Multicentric Castleman Disease 50
Idiopathic Multicentric Castleman's Disease 50
Multicentric Giant Lymph Node Hyperplasia 50
Multi-Centric Castleman's Disease 69
Pmcd 50
Mcd 50

Classifications:



Summaries for Multicentric Castleman Disease

NIH Rare Diseases : 50 multicentric castleman disease (mcd) is a rare condition that affects the lymph nodes and related tissues. it is a form of castleman disease that is "systemic" and affects multiple sets of lymph nodes and other tissues throughout the body (as opposed to unicentric castleman disease which has more "localized" effects). the signs and symptoms of mcd are often nonspecific and blamed on other, more common conditions. they can vary but may include fever; weight loss; fatigue; night sweats; enlarged lymph nodes; nausea and vomiting; and an enlarged liver or spleen. the eact underlying cause is unknown. treatment may involve immunotherapy, chemotherapy, corticosteroid medications and/or anti-viral drugs. last updated: 6/25/2015

MalaCards based summary : Multicentric Castleman Disease, also known as multicentric plasma cell variant of castleman's disease, is related to lupus erythematosus and kaposi sarcoma, and has symptoms including fever An important gene associated with Multicentric Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Ganciclovir and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and spleen, and related phenotypes are hematopoietic system and immune system

Related Diseases for Multicentric Castleman Disease

Diseases related to Multicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
id Related Disease Score Top Affiliating Genes
1 lupus erythematosus 29.8 CRP F3 IL6
2 kaposi sarcoma 11.9
3 metaphyseal chondrodysplasia, schmid type 11.6
4 castleman disease 11.5
5 human herpesvirus 8 11.4
6 unicentric castleman disease 11.0
7 coloboma of iris 10.3 CRP IL6
8 sarcoma 10.3
9 holocarboxylase synthetase deficiency 10.3 IL10 IL21
10 fallopian tube serous adenocarcinoma 10.3 CRP IL10 IL6
11 atrophy of prostate 10.2 CRP IL10 IL6
12 chordoid meningioma 10.2 CRP IL10 IL6
13 choroiditis 10.2 CRP IL10 IL6
14 infancy electroclinical syndrome 10.2 CRP IL10 IL6
15 amelogenesis imperfecta 10.2 CRP IL10 IL6
16 cutaneous sclerosis 10.2 CRP IL6
17 ureter inverted papilloma 10.2 IL10 IL6
18 asbestosis 10.2 CRP IL10 IL6
19 secretory diarrhea myopathy and deafness 10.2 CRP F3 IL6
20 asymptomatic neurosyphilis 10.2 IFNG IL10
21 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 10.2 CRP IL10 IL6
22 mixed mineral dust pneumoconiosis 10.2 CRP IFNG IL6
23 granulomatous hepatitis 10.2 CRP F3 IL6
24 megaloblastic anemia 10.2 CRP F3 IL10
25 common peroneal nerve lesion 10.2 IL5 IL6
26 stiff-person syndrome 10.2 CRP IFNG IL6
27 lepromatous leprosy 10.2 IFNG IL10 IL6
28 rift valley fever 10.2 CRP IFNG IL6
29 cyclosporiasis 10.2 IFNG IL10 IL6
30 conduct disorder 10.2 IFNG IL10 IL6
31 pancreatic signet ring cell adenocarcinoma 10.2 IFNG IL10 IL6
32 ectodermal dysplasia bartalos type 10.2 IFNG IL10 IL6
33 lacrimal system cancer 10.2 CRP IL10 IL6
34 hepatitis 10.2 IFNG IL10 IL6
35 premature menopause 10.2 CRP IL5 IL6
36 congenital chloride diarrhea 10.2 CRP F3 IL6
37 erb-duchenne and dejerine-klumpke palsies 10.2 IFNG IL10 IL6
38 usher syndrome, type 2a 10.2 IFNG IL10 IL6
39 orbital osteomyelitis 10.2 IFNG IL10 IL6
40 acrodysplasia with ossification abnormalities, short stature and fibular hypoplasia 10.2 F3 F8
41 causalgia 10.2 IFNG IL10 IL6
42 shoulder impingement syndrome 10.2 CRP IL6
43 burns 10.2 IFNG IL10 IL6
44 unilateral multicystic dysplastic kidney 10.2 CRP IL6
45 gastroschisis abdominal wall defects, included 10.2 IFNG IL5
46 aortic atherosclerosis 10.2 IL5 IL6
47 classic type lipoma 10.2 IFNG IL10 IL6
48 blue toe syndrome 10.2 IFNG IL10 IL6
49 vulvar nodular hidradenoma 10.2 IFNG IL10 IL6
50 hallucinogen dependence 10.2 IFNG IL10 IL6

Graphical network of the top 20 diseases related to Multicentric Castleman Disease:



Diseases related to Multicentric Castleman Disease

Symptoms & Phenotypes for Multicentric Castleman Disease

UMLS symptoms related to Multicentric Castleman Disease:


fever

MGI Mouse Phenotypes related to Multicentric Castleman Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.14 ABCB1 BCL6 F3 F8 ID1 IFNG
2 immune system MP:0005387 10.1 ABCB1 BCL6 CRP F3 F8 ID1
3 homeostasis/metabolism MP:0005376 10.07 ABCB1 BCL6 CRP F3 F8 IFNG
4 cardiovascular system MP:0005385 10.03 ABCB1 BCL6 CRP F3 ID1 IFNG
5 liver/biliary system MP:0005370 9.8 ABCB1 BCL6 ID1 IFNG IL10 IL5
6 neoplasm MP:0002006 9.7 IL6 PAX5 F3 ID1 IFNG IL10
7 reproductive system MP:0005389 9.56 ABCB1 BCL6 F8 ID1 IFNG IL10
8 respiratory system MP:0005388 9.17 BCL6 F3 ID1 IFNG IL10 IL5

Drugs & Therapeutics for Multicentric Castleman Disease

Drugs for Multicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
2
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
3 Ganciclovir triphosphate Phase 4,Phase 2
4 Anti-Infective Agents Phase 4,Phase 2,Phase 1
5 Antiviral Agents Phase 4,Phase 2
6
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
7
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
8
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
9
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
10
Zidovudine Approved Phase 2 30516-87-1 35370
11
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
12
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Everolimus Approved Phase 2 159351-69-6 6442177
15
Lenograstim Approved Phase 2 135968-09-1
16
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
17
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
18 Pomalidomide Approved Phase 1, Phase 2 19171-19-8
19 Siltuximab Approved Phase 1, Phase 2, Early Phase 1 541502-14-1
20
Doxil Approved June 1999 Phase 2,Phase 1 31703
21 interferons Phase 2
22 Alkylating Agents Phase 2,Phase 1
23 glucocorticoids Phase 2,Phase 1
24 Adjuvants, Immunologic Phase 2
25 Topoisomerase Inhibitors Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 2
27 Hormone Antagonists Phase 2,Phase 1
28 Hormones Phase 2,Phase 1
29 Angiogenesis Inhibitors Phase 2,Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 2,Phase 1
33 Etoposide phosphate Phase 2,Phase 1
34 Immunoglobulins Phase 1, Phase 2, Early Phase 1
35 Anti-HIV Agents Phase 2
36 Antibodies, Monoclonal Phase 1, Phase 2, Early Phase 1
37 Immunosuppressive Agents Phase 2,Phase 1
38 Anti-Inflammatory Agents Phase 2,Phase 1
39 Interferon-alpha Phase 2
40 Antifungal Agents Phase 2
41 Antimetabolites Phase 2
42 Anti-Retroviral Agents Phase 2
43 Antibiotics, Antitubercular Phase 2,Phase 1
44 Reverse Transcriptase Inhibitors Phase 2
45 Antibodies Phase 1, Phase 2, Early Phase 1
46 Antimitotic Agents Phase 2,Phase 1
47 Antirheumatic Agents Phase 2,Phase 1
48 Antineoplastic Agents, Alkylating Phase 2,Phase 1
49 Antineoplastic Agents, Hormonal Phase 2,Phase 1
50 Antineoplastic Agents, Phytogenic Phase 2,Phase 1

Interventional clinical trials:

(show all 19)
id Name Status NCT ID Phase
1 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4
2 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2
3 TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03043105 Phase 2
4 Tocilizumab for KSHV-Associated Multicentric Castleman Disease Recruiting NCT01441063 Phase 2
5 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting NCT00092222 Phase 2
6 Siltuximab in Schizophrenia Recruiting NCT02796859 Phase 1, Phase 2
7 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Active, not recruiting NCT01400503 Phase 2
8 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Active, not recruiting NCT01024036 Phase 2
9 Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy Terminated NCT00127569 Phase 2
10 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2
11 A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Completed NCT01183598 Phase 1
12 Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Recruiting NCT02659930 Phase 1
13 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1
14 Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Completed NCT00695422
15 Unlock the Cell: Castleman's Disease Flow Cytometry Study Recruiting NCT02853968
16 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
17 Castleman Disease Collaborative Network Biobank Recruiting NCT02871050
18 International Registry for Patients With Castleman Disease Recruiting NCT02817997
19 Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Withdrawn NCT02805868 Early Phase 1

Search NIH Clinical Center for Multicentric Castleman Disease

Genetic Tests for Multicentric Castleman Disease

Anatomical Context for Multicentric Castleman Disease

MalaCards organs/tissues related to Multicentric Castleman Disease:

39
Lymph Node, Liver, Spleen, Bone, Bone Marrow, B Cells, T Cells

Publications for Multicentric Castleman Disease

Articles related to Multicentric Castleman Disease:

(show top 50) (show all 136)
id Title Authors Year
1
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. ( 28087540 )
2017
2
Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. ( 27221364 )
2016
3
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. ( 26634298 )
2016
4
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. ( 26805758 )
2016
5
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. ( 26980221 )
2016
6
Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease. ( 27741115 )
2016
7
Atypical presentation of multicentric Castleman disease in a pediatric patient: pleural and pericardial effusion. ( 26614115 )
2016
8
Multicentric Castleman disease: Where are we now? ( 27296355 )
2016
9
Human Herpesvirus Type 8-positive Multicentric Castleman Disease. ( 27133959 )
2016
10
Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports. ( 26598921 )
2016
11
A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination. ( 26948831 )
2016
12
Unicentric versus Multicentric Castleman Disease. ( 27618317 )
2016
13
iNKT and memory B cells alterations in HHV-8 multicentric Castleman disease. ( 28060720 )
2016
14
Bone marrow manifestations in multicentric Castleman disease. ( 26817834 )
2016
15
(18)F-FDG PET/CT in multicentric Castleman disease: a case report. ( 26904580 )
2016
16
TAFRO syndrome: An atypical variant of KSHV-negative multicentric Castleman disease. ( 26663467 )
2016
17
Leukemic phase of a large B-cell lymphoma arising in KSHV-associated multicentric Castleman disease. ( 26756053 )
2015
18
KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. ( 24771491 )
2015
19
(Multicentric Castleman Disease with Monoclonal Incomplete IgH Restriction: A Rare Coexistence). ( 26490523 )
2015
20
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. ( 26327301 )
2015
21
Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. ( 25208471 )
2015
22
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease. ( 26394632 )
2015
23
Siltuximab for Multicentric Castleman Disease-Letter. ( 26473194 )
2015
24
Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report. ( 26137030 )
2015
25
Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. ( 25900626 )
2015
26
Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi. ( 26242311 )
2015
27
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. ( 26124203 )
2015
28
18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters. ( 25828248 )
2015
29
Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome. ( 25093377 )
2015
30
Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years. ( 26666616 )
2015
31
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. ( 25601959 )
2015
32
Multicentric Castleman disease presenting with fever. ( 25282064 )
2014
33
Multicentric Castleman disease mimicking IgG4-related disease: A case report. ( 25528859 )
2014
34
Siltuximab for multicentric Castleman disease. ( 25110138 )
2014
35
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. ( 24622327 )
2014
36
Bone Marrow Involvement in Multicentric Castleman Disease in a HIV Negative Patient. ( 25332537 )
2014
37
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. ( 24387011 )
2014
38
Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. ( 25331113 )
2014
39
Successful single-lung transplantation for multicentric Castleman disease. ( 25193223 )
2014
40
Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. ( 24174627 )
2013
41
Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance. ( 24019247 )
2013
42
Autoimmune hemolytic anemia with warm-reactive immunoglobulin M antibody in multicentric Castleman disease. ( 23180435 )
2013
43
Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. ( 24319170 )
2013
44
Parsonage-Turner syndrome during the treatment of HIV/HHV8-related multicentric Castleman disease. ( 24365755 )
2013
45
Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. ( 23426475 )
2013
46
Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. ( 23596117 )
2013
47
Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody. ( 22638145 )
2012
48
Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. ( 22729151 )
2012
49
Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome. ( 22448005 )
2012
50
Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy. ( 22767345 )
2012

Variations for Multicentric Castleman Disease

Expression for Multicentric Castleman Disease

Search GEO for disease gene expression data for Multicentric Castleman Disease.

Pathways for Multicentric Castleman Disease

Pathways related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 ABCB1 IFNG IL10 IL21 IL5 IL6
2
Show member pathways
12.46 IFNG IL10 IL21 IL5 IL6
3 12.43 BCL6 IFNG IL10 PAX5
4
Show member pathways
12.32 IFNG IL10 IL5 IL6
5
Show member pathways
12.01 IFNG IL10 IL5 IL6
6
Show member pathways
11.89 IFNG IL10 IL21 IL5 IL6
7 11.88 BCL6 IL10 IL6
8 11.83 IFNG IL10 IL5 IL6
9
Show member pathways
11.82 IFNG IL21 IL6
10 11.79 IFNG IL10 IL6
11 11.73 CCL4 IFNG IL6
12
Show member pathways
11.73 IFNG IL10 IL21 IL6
13 11.71 IFNG IL5 IL6
14 11.68 IFNG IL10 IL5
15 11.66 IFNG IL10 IL6
16 11.59 IFNG IL10 IL6
17 11.56 BCL6 IL10 IL5
18 11.55 CCL4 IL5 IL6
19 11.43 CCL4 IL10 IL6
20 11.42 IFNG IL10 IL6
21 11.4 IFNG IL10 IL5
22
Show member pathways
11.31 CCL4 IFNG IL10
23 11.23 IFNG IL10 IL6
24 11.18 BCL6 IL10 IL21 PAX5
25 11.16 IFNG IL5 IL6
26 11.02 IFNG IL10 IL5
27 10.95 CCL4 IL10 IL21 IL5 IL6
28 10.95 BCL6 IL10 IL21 IL5 IL6 PAX5
29 10.93 CRP IL6
30 10.85 ID1 PAX5
31 10.82 IL5 IL6
32 10.73 IFNG IL10 IL5 IL6

GO Terms for Multicentric Castleman Disease

Cellular components related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CCL4 CRP F3 F8 IFNG IL10
2 extracellular space GO:0005615 9.28 CCL4 CRP F3 F8 IFNG IL10

Biological processes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.9 CRP ID1 IFNG IL6
2 response to drug GO:0042493 9.88 ABCB1 IFNG IL10 IL6
3 cellular response to lipopolysaccharide GO:0071222 9.78 IFNG IL10 IL6
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.74 IL10 IL5 IL6
5 positive regulation of neuron differentiation GO:0045666 9.7 BCL6 IFNG IL6
6 positive regulation of T cell proliferation GO:0042102 9.65 IFNG IL21 IL6
7 immune response GO:0006955 9.63 CCL4 IFNG IL10 IL21 IL5 IL6
8 positive regulation of JAK-STAT cascade GO:0046427 9.61 IL5 IL6
9 humoral immune response GO:0006959 9.61 IFNG IL6 PAX5
10 negative regulation of growth of symbiont in host GO:0044130 9.59 IFNG IL10
11 cellular response to hepatocyte growth factor stimulus GO:0035729 9.58 IL10 IL6
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 IFNG IL21 IL6
13 positive regulation of immunoglobulin secretion GO:0051024 9.56 IL5 IL6
14 positive regulation of protein import into nucleus, translocation GO:0033160 9.55 IFNG IL6
15 positive regulation of tyrosine phosphorylation of Stat1 protein GO:0042511 9.54 IFNG IL21
16 positive regulation of B cell proliferation GO:0030890 9.54 BCL6 IL21 IL5
17 negative regulation of lipid storage GO:0010888 9.51 CRP IL6
18 positive regulation of MHC class II biosynthetic process GO:0045348 9.49 IFNG IL10
19 type 2 immune response GO:0042092 9.46 BCL6 IL10
20 acute-phase response GO:0006953 9.43 CRP F8 IL6
21 neutrophil apoptotic process GO:0001781 9.32 IFNG IL6
22 defense response to protozoan GO:0042832 9.13 IFNG IL10 IL6
23 inflammatory response GO:0006954 9.1 BCL6 CCL4 CRP IL10 IL5 IL6

Molecular functions related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CCL4 IFNG IL10 IL21 IL5 IL6

Sources for Multicentric Castleman Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....